Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimiliano Ruscica

Showing results (1-10 of 188) with videos related to

Pageof 19
Sort By:
Endocrine|April 3, 2016
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemiaNicola Ferri, Massimiliano Ruscica
European Heart Journal Supplements : Journal of the European Society of Cardiology|April 24, 2023
Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acidNicola Ferri, Alberto Corsini, Massimiliano Ruscica
Vitamins and Hormones|September 29, 2012
Adiponectin interactions in bone and cartilage biology and diseaseMassimiliano Ruscica, Liliana Steffani, Paolo Magni
Current Atherosclerosis Reports|March 11, 2022
The Role of High-Density Lipoprotein Cholesterol in 2022Cesare R Sirtori, Alberto Corsini, Massimiliano Ruscica
European Heart Journal Supplements : Journal of the European Society of Cardiology|November 16, 2022
Role of lipoprotein(a) in plaque progressionMassimiliano Ruscica, Alessandra S Rizzuto, Alberto Corsini
Journal of Clinical Medicine|August 29, 2024
Correction: Ferri et al. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. <i>J. Clin. Med.</i> 2024, <i>13</i>, 943Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Journal of Clinical Medicine|February 24, 2024
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative ReviewNicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Expert Opinion on Investigational Drugs|March 28, 2017
PPAR-α agonists are still on the rise: an update on clinical and experimental findingsNicola Ferri, Alberto Corsini, Cesare Sirtori, et al.
Peptides|January 6, 2007
Role of neuropeptide Y and its receptors in the progression of endocrine-related cancerMassimiliano Ruscica, Elena Dozio, Marcella Motta, et al.
Frontiers in Cardiovascular Medicine|June 28, 2023
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative reviewErica Gianazza, Chiara Macchi, Cristina Banfi, et al.
Pageof 19

Showing results (1-10 of 188) with videos related to

Sort By:
Pageof 19
Endocrine|April 3, 2016
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemiaNicola Ferri, Massimiliano Ruscica
European Heart Journal Supplements : Journal of the European Society of Cardiology|April 24, 2023
Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acidNicola Ferri, Alberto Corsini, Massimiliano Ruscica
Vitamins and Hormones|September 29, 2012
Adiponectin interactions in bone and cartilage biology and diseaseMassimiliano Ruscica, Liliana Steffani, Paolo Magni
Current Atherosclerosis Reports|March 11, 2022
The Role of High-Density Lipoprotein Cholesterol in 2022Cesare R Sirtori, Alberto Corsini, Massimiliano Ruscica
European Heart Journal Supplements : Journal of the European Society of Cardiology|November 16, 2022
Role of lipoprotein(a) in plaque progressionMassimiliano Ruscica, Alessandra S Rizzuto, Alberto Corsini
Journal of Clinical Medicine|August 29, 2024
Correction: Ferri et al. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. <i>J. Clin. Med.</i> 2024, <i>13</i>, 943Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Journal of Clinical Medicine|February 24, 2024
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative ReviewNicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Expert Opinion on Investigational Drugs|March 28, 2017
PPAR-α agonists are still on the rise: an update on clinical and experimental findingsNicola Ferri, Alberto Corsini, Cesare Sirtori, et al.
Peptides|January 6, 2007
Role of neuropeptide Y and its receptors in the progression of endocrine-related cancerMassimiliano Ruscica, Elena Dozio, Marcella Motta, et al.
Frontiers in Cardiovascular Medicine|June 28, 2023
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative reviewErica Gianazza, Chiara Macchi, Cristina Banfi, et al.
Pageof 19